Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J Mitchell

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Journal of Health Economics and Outcomes Research|February 16, 2026
Trial Interviews to Explore Glycogen Storage Disease Type Ia Patient Experiences Following Gene TherapyDiane M Turner-Bowker, Jessica Butler, Shayna Egan, et al.
Molecular Genetics and Metabolism|July 25, 2018
Safety issues associated with dietary management in patients with hepatic glycogen storage diseaseThomas A H Steunenberg, Fabian Peeks, Irene J Hoogeveen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 11, 2012
Achieving the "triple aim" for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence frameworkBeth K Potter, Pranesh Chakraborty, Jonathan B Kronick, et al.
JIMD Reports|November 22, 2017
Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase AlfaKenneth I Berger, Barbara K Burton, Gregory D Lewis, et al.
Molecular Genetics and Metabolism Reports|September 14, 2016
Pregnancy in patients with mucopolysaccharidosis: a case seriesFiona J Stewart, Andrew Bentley, Barbara K Burton, et al.
Molecular Genetics and Metabolism|December 18, 2017
Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension studyChristian J Hendriksz, Rossella Parini, Moeenaldeen D AlSayed, et al.
Orphanet Journal of Rare Diseases|October 31, 2025
Long-term outcomes of elosulfase alfa enzyme replacement therapy in adults with MPS IVA: a sub-analysis of the Morquio A Registry Study (MARS)Karolina M Stepien, Barbara K Burton, Michael B Bober, et al.
Journal of Inherited Metabolic Disease|August 25, 2016
Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndromeChristian J Hendriksz, Kenneth I Berger, Rossella Parini, et al.
American Journal of Medical Genetics. Part A|June 13, 2015
Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot studyBarbara K Burton, Kenneth I Berger, Gregory D Lewis, et al.
Molecular Genetics and Metabolism|September 10, 2022
Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfaJohn J Mitchell, Barbara K Burton, Michael B Bober, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Journal of Health Economics and Outcomes Research|February 16, 2026
Trial Interviews to Explore Glycogen Storage Disease Type Ia Patient Experiences Following Gene TherapyDiane M Turner-Bowker, Jessica Butler, Shayna Egan, et al.
Molecular Genetics and Metabolism|July 25, 2018
Safety issues associated with dietary management in patients with hepatic glycogen storage diseaseThomas A H Steunenberg, Fabian Peeks, Irene J Hoogeveen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 11, 2012
Achieving the "triple aim" for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence frameworkBeth K Potter, Pranesh Chakraborty, Jonathan B Kronick, et al.
JIMD Reports|November 22, 2017
Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase AlfaKenneth I Berger, Barbara K Burton, Gregory D Lewis, et al.
Molecular Genetics and Metabolism Reports|September 14, 2016
Pregnancy in patients with mucopolysaccharidosis: a case seriesFiona J Stewart, Andrew Bentley, Barbara K Burton, et al.
Molecular Genetics and Metabolism|December 18, 2017
Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension studyChristian J Hendriksz, Rossella Parini, Moeenaldeen D AlSayed, et al.
Orphanet Journal of Rare Diseases|October 31, 2025
Long-term outcomes of elosulfase alfa enzyme replacement therapy in adults with MPS IVA: a sub-analysis of the Morquio A Registry Study (MARS)Karolina M Stepien, Barbara K Burton, Michael B Bober, et al.
Journal of Inherited Metabolic Disease|August 25, 2016
Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndromeChristian J Hendriksz, Kenneth I Berger, Rossella Parini, et al.
American Journal of Medical Genetics. Part A|June 13, 2015
Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot studyBarbara K Burton, Kenneth I Berger, Gregory D Lewis, et al.
Molecular Genetics and Metabolism|September 10, 2022
Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfaJohn J Mitchell, Barbara K Burton, Michael B Bober, et al.
Pageof 8